6 assets in Bladder Squamous Cell Carcinoma

Therapeutic assets addressing Bladder Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Bladder Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Nivolumab Bladder Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Ipilimumab Bladder Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	B (59)
Atezolizumab Bladder Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Bladder Squamous Cell Carcinoma	Emory University	P2	CCC (53)
Pembrolizumab Bladder Squamous Cell Carcinoma	Emory University	P2	CCC (53)